Company Overview of AbGenomics International, Inc.
AbGenomics International, Inc., a biopharmaceutical company, focuses on the discovery and development of antibody therapeutics for the treatment of cancer and immune related inflammatory diseases. It offers AbGn-168, an immunomodulating investigational therapeutic antibody against CD162 that induces apoptosis of late-stage activated T cells and other immune cells, as well as spare naive, regulatory, and memory T cells; various animal disease models, such as CIA, NOD, and allergy, as well as transplantation rejection/GVHD in murine and DTH in non-human primate; and autoimmune diseases, including rheumatoid arthritis, Crohn's disease, lupus, and psoriasis. The company also provides antibody-7 ...
4984 El Camino Real
Los Altos, CA 94022
Founded in 2000
Key Executives for AbGenomics International, Inc.
Founder, Chairman of the Board and Chief Executive Officer
Director of Operation, Corporate Secretary and Director
Director of IP Management & Quality Assurance
Director of Project & Alliance Managements
Compensation as of Fiscal Year 2014.
AbGenomics International, Inc. Key Developments
AbGenomics International, Inc. Presents at 13th Annual BIO Investor Forum, Oct-08-2014 02:30 PM
Sep 9 14
AbGenomics International, Inc. Presents at 13th Annual BIO Investor Forum, Oct-08-2014 02:30 PM. Venue: The Palace Hotel, San Francisco, CA 94105, United States.
AbGenomics International, Inc. Presents at BioPharm America 2013, Sep-18-2013 03:15 PM
Aug 13 13
AbGenomics International, Inc. Presents at BioPharm America 2013, Sep-18-2013 03:15 PM. Venue: Westin Boston Waterfront Hotel, Boston, Massachusetts, United States.
AbGenomics International, Inc. Raises $9.6 Million in Financing
Jul 17 13
AbGenomics International, Inc. has raised $9.6 million in a financing round in private placement.
Similar Private Companies By Industry
Recent Private Companies Transactions
October 3, 2014
August 13, 2014